There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine candidate for norovirus (NoV) infections.

A new vaccine that could stop people from developing the vomiting bug norovirus is on trial in the UK. The mRNA vaccine from Moderna will enter the final stages of testing within the next two weeks, according to health officials,

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

The new mRNA vaccine from Moderna will enter final stages of testing within the next two weeks, with results so far showing it creates a “strong immune response”.

A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

A vaccine to protect against the winter vomiting bug norovirus is set for a year-long trial by the UK’s National Health Service (NHS) after early results showed it creates a “strong immune response.” The Moderna-funded research project plans to work alongside the NHS organizations to recruit members of the public to test the new vaccine over the next year.

Wes Streeting said the virus places the health service under 'huge strain' every winter and costs taxpayers around £100million a year.